172 related articles for article (PubMed ID: 34046343)
1. Anlotinib Combined With Chemotherapy for Recurrence of Pulmonary Sarcomatoid Cancer Previously Surgically Treated: A Case Report and Literature Review.
Li J; Liang H; He J; Sui X; Qin Y
Front Oncol; 2021; 11():639168. PubMed ID: 34046343
[TBL] [Abstract][Full Text] [Related]
2. Anlotinib combined with chemotherapy and immunotherapy for advanced pulmonary sarcomatoid cancer: a case report and literature review.
Piao MN; Ma XT; Tankere P; Liam CK; Li JL; Wang JP
Ann Transl Med; 2022 Sep; 10(18):1030. PubMed ID: 36267791
[TBL] [Abstract][Full Text] [Related]
3. Case report: Sintilimab combined with anlotinib as neoadjuvant chemotherapy for metastatic bone tumor resection in patients with PSC.
Bao Z; Yu X; Zheng K; Zhai K; Cui H; Xu M
Front Immunol; 2024; 15():1372279. PubMed ID: 38756778
[TBL] [Abstract][Full Text] [Related]
4. Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib-a case report.
Li YF; Zhao XF; Tian Y; Xiao XY; Yan CY; Shen H
Front Genet; 2022; 13():949989. PubMed ID: 35938033
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review.
Wu S; Wu S; Liao X; Zhou C; Qiu F; Wang C; Zhong W
Front Immunol; 2023; 14():1274937. PubMed ID: 37936698
[TBL] [Abstract][Full Text] [Related]
6. Case report: Successful treatment of advanced pulmonary sarcomatoid carcinoma with BUBIB
Huang N; Qu T; Zhang C; Li J
Front Oncol; 2024; 14():1269148. PubMed ID: 38414747
[TBL] [Abstract][Full Text] [Related]
7. Dramatic Response of Pulmonary Sarcomatoid Carcinoma to Nivolumab Combined with Anlotinib: A Case Report.
Jin C; Yang B
Case Rep Oncol; 2020; 13(2):601-605. PubMed ID: 32595469
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment.
Dai G; He L; Yan Q; Li Y; Huang Y; Li B; Wang G
Front Oncol; 2023; 13():1167516. PubMed ID: 37456237
[TBL] [Abstract][Full Text] [Related]
9. Successful Treatment of an Elderly Patient With Combined Small Cell Lung Cancer Receiving Anlotinib: A Case Report.
Gan Y; Liu P; Luo T
Front Oncol; 2021; 11():775201. PubMed ID: 34858856
[TBL] [Abstract][Full Text] [Related]
10. Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review.
Wen Y; Dong Y; Yi L; Yang G; Xiao M; Li Q; Zhao C; Ye D; Yao Y
Front Oncol; 2023; 13():1241475. PubMed ID: 37920159
[TBL] [Abstract][Full Text] [Related]
11. A case report: A new promising treatment for pulmonary sarcomatoid carcinoma - Tislelizumab and Anlotinib combined with local radiotherapy.
Cai R; Liu Y; Sha H; Yu J; Fang Y; Zhou G; Shen B
Heliyon; 2023 Nov; 9(11):e21902. PubMed ID: 38027958
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report.
Wang J; Li X; Zhou J; Qiu D; Zhang M; Sun L; Li SC
Front Oncol; 2023; 13():1043244. PubMed ID: 37091182
[TBL] [Abstract][Full Text] [Related]
13. Synchronal pulmonary sarcomatoid carcinoma and lung adenocarcinoma EML4-ALK fusion: A case report.
Wang M; Gong Y; Cheng Y; Yang L; Wang W; Lei X
Oncol Lett; 2022 Oct; 24(4):343. PubMed ID: 36072009
[TBL] [Abstract][Full Text] [Related]
14. Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report.
Chen P; Yu M; Zhang JL; Chen WY; Zhu L; Song Y; Jiang CY; Zhang S
World J Clin Cases; 2020 Jul; 8(13):2876-2884. PubMed ID: 32742998
[TBL] [Abstract][Full Text] [Related]
15. Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study.
Liu J; Deng YT; Jiang Y
Invest New Drugs; 2021 Apr; 39(2):330-336. PubMed ID: 32974853
[TBL] [Abstract][Full Text] [Related]
16. Durable efficacy of anlotinib in a patient with advanced thymic squamous cell carcinoma after multiline chemotherapy and apatinib: A case report and literature review.
Zuo R; Zhang C; Lin L; Meng Z; Wang Y; Su Y; Abudurazik M; Du Y; Chen P
Thorac Cancer; 2020 Nov; 11(11):3383-3387. PubMed ID: 32997432
[TBL] [Abstract][Full Text] [Related]
17. Case Report: Anlotinib Reverses Nivolumab Resistance in Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma With FGFR3 Gene Amplification.
Liu Y; Long L; Liu J; Zhu L; Luo F
Front Oncol; 2021; 11():749682. PubMed ID: 34692530
[TBL] [Abstract][Full Text] [Related]
18. Use of anlotinib in intra-abdominal desmoplastic small round cell tumors: a case report and literature review.
Chen HM; Feng G
Onco Targets Ther; 2019; 12():57-61. PubMed ID: 30588030
[TBL] [Abstract][Full Text] [Related]
19. A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer.
Wang HY; Chu JF; Zhao Y; Tang H; Wang LL; Zhou MQ; Yan Z; Liu YY; Yao ZH
Cancer Manag Res; 2020; 12():3827-3834. PubMed ID: 32547218
[TBL] [Abstract][Full Text] [Related]
20. Case Report: A Case of Locally Advanced Pancreatic Cancer Which Achieved Progression Free for Over 12 Months by Subsequent Therapy with Anlotinib Hydrochloride Plus Tegafur-Gimeracil-Oteracil Potassium (TS-1).
Luo D; Liao S; Li Q; Lin Y; Wei J; Li Y; Liao X
Front Oncol; 2022; 12():862600. PubMed ID: 35847852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]